Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

DNA vaccine trial aims to train body to fight hepatitis c

NCT ID NCT02772003

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 38 times

Summary

This early-stage trial tests a DNA vaccine for people with long-term hepatitis C infection. The vaccine is designed to teach the immune system to recognize and attack the virus, potentially lowering the risk of liver cancer. About 33 adults with active hepatitis C will receive the vaccine to check for side effects and find the best dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Case Western Reserve University

    Cleveland, Ohio, 44106, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Temple University Hospital

    Philadelphia, Pennsylvania, 19140, United States

  • University of Puerto Rico

    San Juan, 00936, Puerto Rico

Conditions

Explore the condition pages connected to this study.